Nikola Curik
Overview
Explore the profile of Nikola Curik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
185
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burda P, Hlavackova A, Polivkova V, Curik N, Laznicka A, Krizkova J, et al.
Mol Metab
. 2024 Aug;
88:102016.
PMID: 39182842
Objective: A prominent, safe and efficient therapy for patients with chronic myeloid leukemia (CML) is inhibiting oncogenic protein BCR::ABL1 in a targeted manner with imatinib, a tyrosine kinase inhibitor. A...
2.
Dolnikova A, Kazantsev D, Klanova M, Pokorna E, Sovilj D, Kelemen C, et al.
Blood Adv
. 2024 May;
8(13):3532-3543.
PMID: 38713893
Venetoclax (VEN), a B-cell lymphoma 2 (BCL2) inhibitor, has a promising single-agent activity in mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), and large BCLs, but remissions were generally short,...
3.
Curik N, Laznicka A, Polivkova V, Krizkova J, Pokorna E, Semerak P, et al.
Leukemia
. 2024 Apr;
38(6):1415-1418.
PMID: 38615117
No abstract available.
4.
Polakova K, Albeer A, Polivkova V, Krutska M, Vlcanova K, Curik N, et al.
Leukemia
. 2023 Dec;
38(2):318-325.
PMID: 38129513
Membrane transporters are important determinants of drug bioavailability. Their expression and activity affect the intracellular drug concentration in leukemic cells impacting response to therapy. Pharmacogenomics represents genetic markers that reflect...
5.
Curik N, Polivkova V, Burda P, Koblihova J, Laznicka A, Kalina T, et al.
Front Oncol
. 2021 Oct;
11:744373.
PMID: 34616685
Somatic mutations are a common molecular mechanism through which chronic myeloid leukemia (CML) cells acquire resistance to tyrosine kinase inhibitors (TKIs) therapy. While most of the mutations in the kinase...
6.
Polivkova V, Benesova A, Zizkova H, Koblihova J, Curik N, Motlova E, et al.
Leukemia
. 2021 Mar;
35(8):2419-2423.
PMID: 33772144
No abstract available.
7.
Srutova K, Curik N, Burda P, Savvulidi F, Silvestri G, Trotta R, et al.
Haematologica
. 2018 Jul;
103(12):2016-2025.
PMID: 30049824
The fusion oncoprotein BCR-ABL1 exhibits aberrant tyrosine kinase activity and it has been proposed that it deregulates signaling networks involving both transcription factors and non-coding microRNAs that result in chronic...
8.
Jaruskova M, Curik N, Hercog R, Polivkova V, Motlova E, Benes V, et al.
J Exp Clin Cancer Res
. 2017 Apr;
36(1):55.
PMID: 28420426
Background: Through high-throughput next-generation sequencing of promoters of solute carrier and ATP-binding cassette genes, which encode drug transporters, we aimed to identify SNPs associated with the response to imatinib administered...
9.
Polivkova V, Rohon P, Klamova H, cerna O, Divoka M, Curik N, et al.
PLoS One
. 2016 May;
11(5):e0155959.
PMID: 27214026
Bone marrow transplantation or ponatinib treatment are currently recommended strategies for management of patients with chronic myeloid leukemia (CML) harboring the T315I mutation and compound or polyclonal mutations. However, in...
10.
Burda P, Vargova J, Curik N, Salek C, Papadopoulos G, Strouboulis J, et al.
PLoS One
. 2016 Mar;
11(3):e0152234.
PMID: 27010793
GATA-1 and PU.1 are two important hematopoietic transcription factors that mutually inhibit each other in progenitor cells to guide entrance into the erythroid or myeloid lineage, respectively. PU.1 controls its...